ES2533362T3 - Preparación para la prevención y/o el tratamiento de síndromes de demencia - Google Patents

Preparación para la prevención y/o el tratamiento de síndromes de demencia Download PDF

Info

Publication number
ES2533362T3
ES2533362T3 ES09156648.9T ES09156648T ES2533362T3 ES 2533362 T3 ES2533362 T3 ES 2533362T3 ES 09156648 T ES09156648 T ES 09156648T ES 2533362 T3 ES2533362 T3 ES 2533362T3
Authority
ES
Spain
Prior art keywords
fraction
vitamin
prevention
treatment
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES09156648.9T
Other languages
English (en)
Other versions
ES2533362T7 (es
Inventor
Amanda Johanne Kiliaan
Robert Johan Joseph Hageman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutricia NV
Original Assignee
Nutricia NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27074171&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2533362(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nutricia NV filed Critical Nutricia NV
Publication of ES2533362T3 publication Critical patent/ES2533362T3/es
Application granted granted Critical
Publication of ES2533362T7 publication Critical patent/ES2533362T7/es
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)

Abstract

Una preparación para su uso en la prevención y/o el tratamiento de la degeneración de la función cerebral, de la degeneración cognitiva y/o de síndromes de demencia, que comprende las siguientes fracciones: a) ácidos grasos poliinsaturados de cadena larga que comprenden al menos uno de los ácidos grasos ω-3 ácido eicosapentaenoico y ácido docosahexaenoico; b) fosfolípidos, fracción que contiene al menos dos fosfolípidos diferentes, seleccionados de entre el grupo que consiste en fosfatidilserina, fosfatidilinositol, fosfatidilcolina y fosfatidiletanolamina; c) compuestos que son un factor en el metabolismo de la metionina, fracción que contiene al menos ácido fólico y vitamina B6, en la que la cantidad de ácido fólico es de al menos 200 μg de ácido fólico por dosis diaria.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
5
10
15
20
E09156648
20-03-2015
degradación de las placas. Un suministro adecuado de sangre puede ayudar adicionalmente a prevenir los procesos oxidativos de degeneración que se observan en muchos trastornos neurológicos, tales como en la enfermedad de Parkinson (en la sustancia negra) y ayudar en la biosíntesis y el metabolismo de los neurotransmisores, tales como el ácido gamma-amino butírico y la dopamina.
Ejemplo 1
Cápsula para su uso por parte de personas con demencia tres veces a día. La cápsula se prepara mediante el uso de métodos conocidos en la técnica y comprende como componentes
activos:
DHA
50 mg
EPA
75 mg
fosfolípidos *
250 mg
ácido fólico
200 μg
vitamina B12
25 mg
Huperzia serrata
100 ug
vitamina B1
100 mg
coenzima Q10
10 mg
vitamina E
200 mg
Gingko biloba
120 mg
* fosfatidilcolina 130 mg, fosfatidilserina 120 mg (sintética)
Ejemplo 2
Pudin para la mejora de afecciones vasculares y de trastornos secundarios tales como síndromes de adherencia. El pudin se basa en leche de vaca, almidón, azúcar y saborizantes, se prepara mediante métodos conocidos en la técnica y comprende como principios activos por ración de 200 ml:
fosfolípidos de huevo 4 g
(proporciona aproximadamente 20 mg de DHA y 20 mg de AA y fosfolípidos, comprende aproximadamente
un 77 % de fosfatidilcolina y un 16 % de fosfatidiletanolamina)
fosfatidilserina 100 mg
aceite de pescado encapsulado (proporciona aproximadamente 30 mg de DHA y 30 mg de EPA) 0,3 g
aceite unicelular (25 mg de AA) 0,06 g
ácido fólico (monoglutamato sintético) 0,3 mg
vitamina B6 (piridoxina) 3 mg
cinc (ZnSO4) 10 mg
magnesio (MgO) 100 mg
vitamina B12 (cianocobalamina) 3 μg
citrato / ácido cítrico 1,2 g
HCl de tiamina 2 mg
vitamina E 20 mg
manganeso (MnO) 10 mg
Ejemplo 3
Concentrado en polvo que consiste en los componentes activos según se proporcionan en el ejemplo 2 y adicionalmente 0,1 g de saborizante de naranja y maltodextrina para formar una masa total de 10 g. Esta cantidad se envasa en un sobrecito y puede usarse para reconstituirse con cualquier bebida (leche, zumo de fruta, etc.).
Ejemplo 4
Polvo para mejorar la función vasoendotelial que consiste en
7
E09156648
20-03-2015
lecitina de soja * 3 g ácido fólico 400 μg vitamina B6 3 mg vitamina B12 4 μg cinc 15 mg magnesio 150 mg ácido cítrico / citrato (pH del producto 7,0) 2,2 g maltodextrinas hasta formar un peso total de 10 g
* fosfatidilcolina:fosfatidiletanolamina:fosfatidilinositol = 24:22:15)
Ejemplo 5
Barra de muesli de aproximadamente 25 g basada en azúcar, cereales y trozos de frutas secas que comprende
como componentes activos:
lecitina de soja *
2 g
aceite de pescado encapsulado
0,6 g
SCO (AA)
0,3 g
ácido fólico
400 μg
piridoxamina
3 mg
cianocobalamina
5 μg
óxido de cinc
30 mg
óxido de magnesio
200 mg
ácido cítrico / citrato pH 6,5 de la mezcla
2 g
extracto de Huperzine serrata
150 μg
extracto de Gingko biloba
200 mg
sulfato de calcio
300 mg
vitamina D
10 μg
* fosfatidilcolina:fosfatidiletanolamina:fosfatidilinositol = 45:26:14) La barra está recubierta con una capa de chocolate.
8

Claims (1)

  1. imagen1
    imagen2
ES09156648T 2000-05-08 2001-05-08 Preparación para la prevención y/o el tratamiento de síndromes de demencia Active ES2533362T7 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56638600A 2000-05-08 2000-05-08
US566386 2000-05-08
US09/703,798 US7226916B1 (en) 2000-05-08 2000-11-02 Preparation for the prevention and/or treatment of vascular disorders
US703798 2000-11-02

Publications (2)

Publication Number Publication Date
ES2533362T3 true ES2533362T3 (es) 2015-04-09
ES2533362T7 ES2533362T7 (es) 2019-02-04

Family

ID=27074171

Family Applications (3)

Application Number Title Priority Date Filing Date
ES01928256T Expired - Lifetime ES2298232T3 (es) 2000-05-08 2001-05-08 Preparado para la prevencion y/o tratamiento de enfermedades vasculares.
ES07120681T Expired - Lifetime ES2326928T3 (es) 2000-05-08 2001-05-08 Preparado par ala prevencion y/o tratamiento de sindromes de demencia.
ES09156648T Active ES2533362T7 (es) 2000-05-08 2001-05-08 Preparación para la prevención y/o el tratamiento de síndromes de demencia

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES01928256T Expired - Lifetime ES2298232T3 (es) 2000-05-08 2001-05-08 Preparado para la prevencion y/o tratamiento de enfermedades vasculares.
ES07120681T Expired - Lifetime ES2326928T3 (es) 2000-05-08 2001-05-08 Preparado par ala prevencion y/o tratamiento de sindromes de demencia.

Country Status (13)

Country Link
US (5) US7226916B1 (es)
EP (5) EP2070519B3 (es)
CN (1) CN1245984C (es)
AT (2) ATE431133T1 (es)
AU (1) AU2001255114A1 (es)
CA (1) CA2408032C (es)
CY (3) CY1107237T1 (es)
DE (2) DE60132081T2 (es)
DK (3) DK1911442T3 (es)
ES (3) ES2298232T3 (es)
HK (1) HK1052439B (es)
PT (3) PT2070519E (es)
WO (1) WO2001084961A2 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2187115T3 (es) * 1999-01-20 2003-05-16 Nutricia Nv Preparado para lactantes.
US7208180B2 (en) 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
KR100680121B1 (ko) * 2001-08-09 2007-02-07 데구사 푸드 인그리디언츠 게엠베하 (리소-)포스파티딜세린을 포함하는 온혈동물에서 스트레스상태의 예방 및 치료용 제제
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
DE10250727B4 (de) * 2002-04-19 2008-07-10 Cargill, Incorporated, Wayzata Matrix mit einer bioaktiven Phospholipid-haltigen Komponente
JP4599604B2 (ja) * 2002-04-19 2010-12-15 カーギル テクスチュアライジング ソリューションズ ドイチュラント ゲゼルシャフト ミット ベシュレクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 生体活性のリン脂質含有成分を含有するマトリックス
DE10217557A1 (de) * 2002-04-19 2003-11-06 Degussa Bioactives Gmbh Funktionsnahrungsmittel enthaltend eine Phospholipid-haltige stabile Matrix
DE10217555A1 (de) * 2002-04-19 2004-02-19 Degussa Bioactives Deutschland Gmbh Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix
CN1665496B (zh) * 2002-05-03 2010-05-05 派普生物保健品公司 Epa和dha在制备二级预防神经性疾患的药物中的用途
BRPI0311909A8 (pt) 2002-06-19 2018-02-06 Nutricia Nv Métodos para a manufatura de uma composição, e para aumentar a capacidade de metilação de um indivíduo, e, composição farmacêutica ou nutricional
EP1388295A1 (en) * 2002-08-07 2004-02-11 Nestec S.A. Cereal based food product comprising DHA
FR2847472B1 (fr) * 2002-11-22 2006-08-11 Synergia Nouvelles compositions pharmaceutiques notamment pour la prevention des pathologies cardio-vasculaires
JP2006516614A (ja) * 2003-02-05 2006-07-06 エヌ．ブイ．・ヌートリシア 敗血症の予防および／または治療のための経腸組成物
RU2005135565A (ru) * 2003-04-17 2006-07-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Поливитаминная и минеральная добавка для беременных женщин
US8703209B2 (en) 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
EP1637134A4 (en) * 2003-06-20 2010-01-27 Mochida Pharm Co Ltd COMPOSITION FOR THE PREVENTION AND TREATMENT OF VARICES
AU2004257756A1 (en) * 2003-07-10 2005-01-27 Carl A. Forest Foods, beverages, condiments, spices and salad dressings with specialized supplements
US8017160B2 (en) * 2003-08-15 2011-09-13 Russell Jaffe Enhancement of magnesium uptake in mammals
DE10340740A1 (de) * 2003-09-04 2005-03-31 Degussa Food Ingredients Gmbh Physiologisch aktive Zusammensetzung auf Phosphatidylserin-Basis
IL158139A0 (en) * 2003-09-25 2004-09-27 Enzymotec Ltd Stabilized formulations of phosphatidyl serine
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
EP1645276A1 (en) * 2004-10-08 2006-04-12 Wageningen Centre for Food Sciences Treatment of neurodegenerative disorders
US20090054523A1 (en) * 2005-01-24 2009-02-26 Morten Bryhn Use of a Fatty Acid Composition Containing DHA for the Production of a Medical Product or a Food Stuff for the Treatment of Amyloidos-Related Diseases
EP1888081B1 (en) 2005-05-23 2016-12-28 Massachusetts Institute of Technology Compositions containing pufa and methods of use thereof
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
EP1951071A2 (en) * 2005-10-18 2008-08-06 Artmed S.r.l. Nutraceutical and pharmaceutical compositions containing choline as adiuvants for the prevention and treatment of retinopathies and glaucoma
US8338397B2 (en) 2006-01-19 2012-12-25 The Regents Of The University Of Michigan Composition and method of treating side effects from antibiotic treatment
US8927528B2 (en) 2006-01-19 2015-01-06 The Regents Of The University Of Michigan Composition for treating hearing loss
US7951845B2 (en) 2006-01-19 2011-05-31 The Regents Of The University Of Michigan Composition and method of treating hearing loss
US9770433B2 (en) 2006-01-19 2017-09-26 The Regents Of The University Of Michigan Composition and method for treating tinnitus
US9889156B2 (en) 2006-01-19 2018-02-13 The Regents Of The University Of Michigan Method for treating noise-induced hearing loss (NIHL)
US10238599B2 (en) 2006-01-19 2019-03-26 The Regents Of The University Of Michigan Composition and method for treating congenital cytomegalovirus induced hearing loss
US9919008B2 (en) 2006-01-19 2018-03-20 The Regents Of The University Of Michigan Method for treating age-related hearing loss (ARHL)
USRE46372E1 (en) 2006-01-19 2017-04-25 The Regents Of The Univerity Of Michigan Method for treating hearing loss
US8871808B2 (en) 2006-06-22 2014-10-28 Ben-Gurion University Of The Negev Research And Development Authority Et Al. Over-production of dihomo linolenic acid by a mutant strain of Parietochloris incisa
EP2046312B1 (en) * 2006-07-14 2020-02-19 Kaydence Pharma AS Pharmaceutical and nutraceutical products comprising vitamin k2
EP2098229A4 (en) 2006-12-28 2010-03-10 Suntory Holdings Ltd NERVE REGENERATION MEDIUM
WO2009002148A1 (en) 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
WO2009002146A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
ES2808406T3 (es) 2007-06-26 2021-02-26 Nutricia Nv Mejora de la memoria en sujetos con un mini examen del estado mental de 24-26
WO2009002145A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
AU2007357796B2 (en) * 2007-08-13 2014-05-08 Ben-Gurion University Of The Negev Research And Development Authority Over-production of dihomo gamma linolenic acid by a mutant strain of Parietochloris incisa
DE102007042557A1 (de) * 2007-09-07 2009-03-19 Membramed Gmbh Neuartige Formulierung von Phospholipiden
CA2702577A1 (en) 2007-10-15 2009-04-23 Jbs United, Inc. Method for increasing performance of offspring
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP2224911A4 (en) * 2007-11-30 2013-05-08 Jbs United Inc METHOD AND COMPOSITION FOR TREATING LUNG HAEMORRHAGIA
ES2697149T3 (es) 2007-12-20 2019-01-22 Nutricia Nv Producto líquido que contiene nucleótidos/nucleósidos
US9034399B2 (en) * 2008-01-03 2015-05-19 Melaleuca, Inc. Dietary compositions for promoting brain health
CN102014896A (zh) * 2008-02-29 2011-04-13 生物实验萨纽斯药物有限公司 包含西坦和肉毒碱的药物组合物及其制备方法
EP2172203A1 (en) * 2008-09-17 2010-04-07 Giuliani S.P.A. Pharmaceutical composition for the treatment of gastrointestinal irritation disorders
CA2777233A1 (en) * 2008-10-13 2010-04-22 Pregnant Princess & Co. Ltd. Compositions and methods for treating varicose veins
DK2429317T4 (da) * 2009-04-17 2019-05-13 Natac Pharma S L Sammensætninger med højt indhold af omega-3-fedtsyrer og med lavt indhold af phytansyre
EP2504039A4 (en) 2009-11-25 2014-07-02 Univ Loma Linda Med HEMOSTATIC TEXTILE BASED ON CHITOSAN
EP2627326A2 (en) * 2010-10-12 2013-08-21 Vifor SA Novel omega-3 and omega-6 fatty acid compositions and uses thereof
CN103797110B (zh) 2011-07-12 2017-08-25 食品安全测试系统公司 沙门氏菌和大肠杆菌的培养基和培养方法以及用于检测沙门氏菌和大肠杆菌的方法
RU2505290C2 (ru) * 2011-10-31 2014-01-27 Общество С Ограниченной Ответственностью "Консорциум-Пик" Фармацевтическая композиция, обладающая свойством снижения эндотелиальной дисфункции при заболеваниях сердечно-сосудистой системы
WO2013138368A1 (en) * 2012-03-12 2013-09-19 Loma Linda University Medical Center Substances and methods for the treatment of cerebral amyloid angiopathy related conditions or diseases
CN103432156A (zh) * 2013-08-30 2013-12-11 深圳奥萨医药有限公司 ω-3脂肪酸和B族维生素的药物组合物及其用途
GB201405033D0 (en) 2014-03-20 2014-05-07 Isis Innovation Combination therapy
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
DE202014102551U1 (de) * 2014-05-30 2015-02-26 Orthomol Pharmazeutische Vertriebs Gmbh Diätetische Zubereitung in Form eines Riegels
US10183044B2 (en) 2015-05-15 2019-01-22 P Tech, Llc Systems and methods for thrombosis prevention
EP3328214B1 (en) 2015-07-29 2020-04-01 Abbott Laboratories Nutritional products having improved lipophilic solubility and bioavailability in an easily mixable form
CN105079009B (zh) * 2015-08-25 2018-05-01 厦门金达威生物科技有限公司 预防和/或治疗心脑血管疾病的组合物
CN107252089A (zh) * 2017-04-05 2017-10-17 吉林省润生特膳食品科技开发有限公司 一种山楂桃仁山药粉及其制备方法
IL275479B2 (en) 2017-12-21 2026-01-01 Univ Osaka Therapeutic material for nervous system disease
CN110404049A (zh) * 2019-07-23 2019-11-05 张明 通过雾化吸入防治心脑血管病和老年痴呆的组合物及应用
FR3099339B1 (fr) * 2019-08-01 2022-06-17 Specialites Pet Food Hydrolysat protéique issu de poissons bleus
CN112843072A (zh) * 2021-01-12 2021-05-28 山东省科学院生物研究所 磷脂在调控血管生成方面的应用
CN113456640A (zh) * 2021-08-26 2021-10-01 烟台大学 石杉碱甲在心肌缺血损伤预防中的应用
AU2022345465A1 (en) 2021-09-17 2024-03-21 N.V. Nutricia Solid composition suitable as a nutritional composition or supplement for animals that suffer from brain related disorders, decline or diseases
IT202200010583A1 (it) * 2022-05-23 2023-11-23 Neilos S R L “Composizione nutraceutica o farmaceutica per l’infertilità maschile”
GB202209414D0 (en) * 2022-06-27 2022-08-10 Aker Biomarine Antarctic As Uses for phospholipid compositions

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2824362A1 (de) 1978-06-01 1979-12-13 Josef Dipl Chem Dr Rer N Klosa Pharmazeutisches praeparat mit l-tryptophan
IT1212900B (it) * 1983-11-17 1989-11-30 Valle Francesco Della Uso terapeutico della fosfatidilserina in malattie del sistema nervoso centrale senza effetti sulla coagulazione sanguigna
AU594066B2 (en) 1985-07-26 1990-03-01 Yeda Research And Development Co. Ltd. A special lipid mixture for membrane fluidization
US4897380A (en) 1985-08-30 1990-01-30 Pollack Robert L Method and composition for relieving dietary-related disorders
US5177082A (en) * 1985-11-05 1993-01-05 Yu Chao Mei Huperzines and analogs
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
JPS63208524A (ja) 1987-02-25 1988-08-30 Nippon Oil & Fats Co Ltd 睡眠リズム改善剤
IL86423A0 (en) 1987-05-19 1988-11-15 Baylor College Medicine Pharmaceutical compositions for the treatment of alzheimer's disease
WO1989002737A1 (en) 1987-09-30 1989-04-06 University Of Florida Treatment of hypertension by chronic administration of l-tryptophan or l-5-hydroxytryptophan
US4837219A (en) * 1987-11-05 1989-06-06 Jeffrey Hutterer Medication for Alzheimer's disease
US5004615A (en) * 1988-04-27 1991-04-02 Bionix Corporation Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory
JP2732109B2 (ja) * 1989-02-10 1998-03-25 正樹 今川 痴呆治療剤
JP2909508B2 (ja) * 1989-02-14 1999-06-23 マルハ株式会社 オキアミリン脂質の分取方法
US6294520B1 (en) 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
JPH02302732A (ja) 1989-05-18 1990-12-14 Seiko Epson Corp 液晶表示装置
US5401730A (en) * 1990-07-06 1995-03-28 The Hope Heart Institute Method for reducing platelet aggregation
US5077069A (en) 1991-01-07 1991-12-31 Kabi Pharmacia Ab Composition of natural antioxidants for the stabilization of polyunsaturated oils
US5108767A (en) 1991-06-10 1992-04-28 Abbott Laboratories Liquid nutritional product for persons receiving renal dialysis
DE4309217A1 (de) * 1992-01-18 1994-07-28 Margarethe Rabien Kombinationspräparat Pantothensäure bzw. Dexpanthen + alpha-Liponesäure + Vitamin E (Muskeldystrophie, Polyneuropathie, Muskelatrophie Atoxie, neue Indikation (alpha-Liponsäure + Pantothensäure) Alzheimersche Krankheit
US5234702A (en) 1992-03-19 1993-08-10 Abbott Laboratories Antioxidant system for powdered nutritional products
US5223285A (en) 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
JPH0717855A (ja) 1992-09-02 1995-01-20 Maruha Corp 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
DE4304394A1 (en) 1993-02-13 1993-09-02 Fresenius Ag Prepn. for nourishment of oncological patients - comprises fats formulation contg. oleic acid, alpha-linolenic acid, etc., and opt. carbohydrate and proteins
EP0700303A4 (en) 1993-05-28 1996-08-21 Abbott Lab ENTERAL NUTRITIONAL PRODUCT
WO1995015750A1 (en) * 1993-12-10 1995-06-15 Hashim Sami A Reducing likelihood of vascular disorders in susceptible patients
FR2714574B1 (fr) 1993-12-31 1996-03-15 Inst Rech Biolog Sa Nouveaux suppléments alimentaires pour la nutrition des très jeunes enfants.
JPH07224142A (ja) 1994-02-08 1995-08-22 Dai Ichi Kogyo Seiyaku Co Ltd エポキシ樹脂及びエポキシ樹脂組成物
WO1995026646A1 (en) 1994-04-01 1995-10-12 Abbott Laboratories Nutritional product for treatment of ulcerative colitis and use thereof
CA2150741A1 (en) 1994-06-17 1995-12-18 Susan Trimbo Pediatric lipid emulsion
JP3053537B2 (ja) 1994-11-08 2000-06-19 株式会社ヤクルト本社 脳機能改善剤
GB9423625D0 (en) * 1994-11-23 1995-01-11 Scotia Holdings Plc Fortified fruit juice
US5589468A (en) 1995-01-13 1996-12-31 Clintec Nutrition Co. Method for providing nutrition to elderly patients
EP0726073A3 (en) * 1995-02-10 1998-07-08 Eduardo Samuel Bleiweiss Pharmaceutical compositions containing at least one of haloperidol, imipramine or trifluoroperazine
JPH08252856A (ja) 1995-03-16 1996-10-01 Asahi Glass Co Ltd 樹脂枠体付き窓用板状体の製造装置
JPH0954212A (ja) * 1995-08-11 1997-02-25 Sharp Corp 位相差フィルム及びその製造方法、並びに液晶表示素子
JP3791951B2 (ja) 1995-11-08 2006-06-28 株式会社ヤクルト本社 多価不飽和脂肪酸含有ホスファチジルセリンを含む油脂組成物の製造方法
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
GB9606736D0 (en) * 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
AU2583397A (en) 1996-04-10 1997-10-29 Chronorx, Llc Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions
AU2738497A (en) 1996-04-24 1997-11-12 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US6077828A (en) 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
JP3664814B2 (ja) * 1996-06-26 2005-06-29 旭化成ケミカルズ株式会社 血中脂質改善剤及び食品添加剤
US6008221A (en) * 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
JPH10140919A (ja) 1996-11-11 1998-05-26 Mika Oosawa 建物空間内の間仕切り構造
EP0843972B1 (en) 1996-11-20 2002-07-31 N.V. Nutricia Nutritional composition comprising fats for the treatment of the metabolic syndrome
JPH10165119A (ja) * 1996-12-10 1998-06-23 Seijiro Yanai イチョウ葉エキス添加強化米及びその製造方法
US6013273A (en) 1997-01-27 2000-01-11 Novartis Nutrition Ag Treatment of endotoxic shock
GB9701675D0 (en) 1997-01-28 1997-03-19 Bridgeman Keith Composition for the treatment of parkinson's disease
CA2280093A1 (en) 1997-02-04 1998-08-06 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
US5843469A (en) * 1997-04-11 1998-12-01 Mcentee; William J. Lipid soluble forms of thiamine for prevention and treatment of age-related cognitive impairment of the nervous system
US6344482B1 (en) 1997-04-23 2002-02-05 Andrew L. Stoll Omega-3 fatty acids in the treatment of bipolar disorder
US5820867A (en) 1997-04-24 1998-10-13 Bewicke; Calverly M. General anti-depressant composition for dietary supplement
WO1998048788A1 (en) 1997-04-29 1998-11-05 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
FR2762993B1 (fr) 1997-05-06 1999-08-13 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
EP0891719A1 (en) 1997-07-14 1999-01-20 N.V. Nutricia Nutritional composition containing methionine
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
AU8925998A (en) 1997-09-03 1999-03-22 Macro Hi-Tech Jv, Ltd. Huperzine a derivatives
EP1032403B1 (en) 1997-10-24 2012-05-02 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
US5922704A (en) * 1997-12-24 1999-07-13 Feeling Fine Company Llc Optimal nutritional supplement for men
FR2773484B1 (fr) * 1998-01-09 2001-03-30 Pierre Moreau Nouvelles compositions a effet synergique entre micronutriments et substances d'origine vivante
JP2002509111A (ja) 1998-01-13 2002-03-26 レクソール サンダウン インコーポレイテッド オトギリソウ及びメチル供与体組成物、並びにその使用
WO1999037155A1 (en) 1998-01-27 1999-07-29 Nutramax Laboratories, Inc. Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances
GB9808579D0 (en) 1998-04-22 1998-06-24 Novartis Nutrition Ag Improvements in or relating to organic compounds
EP1075481A1 (en) 1998-05-04 2001-02-14 Andreas Johannes Kesel Monomeric, oligomeric and polymeric knoevenagel condensation products
CN1235770A (zh) * 1998-05-15 1999-11-24 武汉华凯保健品开发有限公司 银杏茶
JP2002517456A (ja) 1998-06-11 2002-06-18 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス 虚血からのニューロンの保護
IT1299195B1 (it) 1998-06-25 2000-02-29 Sigma Tau Healthscience Spa Composizione ad attivita' neuroprotettiva per la prevenzione ed il trattamento delle alterazioni nervose e comportamentali legate a stati
CA2340223A1 (en) 1998-08-12 2000-02-24 Morinaga Milk Industry Co., Ltd. Nutritional compositions for preventing or treating hyperlipoproteinemia
JP2000148134A (ja) 1998-11-13 2000-05-26 Seiko Epson Corp 画像表示方法および画像処理装置
FR2788437B1 (fr) 1999-01-14 2006-08-11 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine vegetale et animale en therapeutique nutritionnelle
US6120814A (en) * 1999-02-22 2000-09-19 Nature's One, Inc. Organic nutritional formula
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US7208180B2 (en) 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
WO2012058461A1 (en) 2010-10-29 2012-05-03 C.R.Bard, Inc. Bioimpedance-assisted placement of a medical device

Also Published As

Publication number Publication date
EP2292210A1 (en) 2011-03-09
EP1911442A3 (en) 2008-05-21
CA2408032C (en) 2012-08-21
US20130157978A1 (en) 2013-06-20
DK2070519T6 (en) 2018-11-19
EP1282365B1 (en) 2007-12-26
US7560447B2 (en) 2009-07-14
EP2070519B1 (en) 2014-12-24
CN1440240A (zh) 2003-09-03
CY1107237T1 (el) 2012-11-21
HK1052439A1 (en) 2003-09-19
PT1911442E (pt) 2009-09-01
EP1282365A2 (en) 2003-02-12
EP2070519A1 (en) 2009-06-17
DE60132081T2 (de) 2008-12-18
DE60132081D1 (de) 2008-02-07
DK1911442T3 (da) 2009-06-08
CA2408032A1 (en) 2001-11-15
US20080193561A1 (en) 2008-08-14
EP2070519B3 (en) 2018-08-22
US20100303784A1 (en) 2010-12-02
US7226916B1 (en) 2007-06-05
HK1052439B (en) 2008-02-29
EP2316426B1 (en) 2016-11-30
DK1282365T3 (da) 2008-03-31
WO2001084961A3 (en) 2002-08-15
ES2533362T7 (es) 2019-02-04
DK2070519T3 (da) 2015-03-30
EP1911442A2 (en) 2008-04-16
CN1245984C (zh) 2006-03-22
PT1282365E (pt) 2008-03-24
CY1109248T1 (el) 2014-07-02
EP2316426A1 (en) 2011-05-04
AU2001255114A1 (en) 2001-11-20
ES2326928T3 (es) 2009-10-21
WO2001084961A2 (en) 2001-11-15
US7772217B2 (en) 2010-08-10
CY1116212T1 (el) 2017-02-08
US8865687B2 (en) 2014-10-21
DE60138742D1 (de) 2009-06-25
US8377912B2 (en) 2013-02-19
ES2298232T3 (es) 2008-05-16
US20070202194A1 (en) 2007-08-30
ATE431133T1 (de) 2009-05-15
PT2070519E (pt) 2015-03-26
ATE381894T1 (de) 2008-01-15
EP1911442B1 (en) 2009-05-13

Similar Documents

Publication Publication Date Title
ES2533362T3 (es) Preparación para la prevención y/o el tratamiento de síndromes de demencia
US6436431B1 (en) Fortified rice bran food product and method for promoting cardiovascular health
JP2016514673A (ja) 改善された認知機能サプリメント
RU2705208C2 (ru) Способ для оценки и лечения или профилактики нарушенных уровней полярных липидов в плазме
WO2010078659A1 (en) Compositions and methods for nutritional prevention and treatment of alzheimer's-associated conditions
US20240316088A1 (en) Solid composition suitable as a nutritional composition or supplement for animals that suffer from brain related disorders, decline or diseases
AU2002320118B2 (en) Fortified ricebran food product and method for promoting cardiovascular health
Sorrentino cardiovascular disease using complementary and alternative medical therapies
US20170020810A1 (en) Nutritional Supplement and Method of Administering the Same
AU2002320118A1 (en) Fortified ricebran food product and method for promoting cardiovascular health